Aktie A2QB4N BROE CAPI
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen BROE CAPI

Aktien

A2QB4N

US11374E1047

BCAC

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
BROE CAPI27 : INDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS - Form 8-K/A
Brookline Capital Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
BROE CAPI27 : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION - Form 8-K
Brookline Capital Acquisition : Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company - Form 8-K
Brookline Capital Acquisition Corp.(NasdaqCM:BCAC) dropped from NASDAQ Composite Index
Apexigen Inc. completed the acquisition of Brookline Capital Acquisition Corp. from Brookline Capital Holdings, LLC, Periscope Capital Inc, Kepos Capital LP and others in a reverse merger transaction.
BROOKLINE CAPITAL ACQUISITION : AND APEXIGEN, INC. ANNOUNCE STOCKHOLDER APPROVAL OF BUSINESS COMBINATION - Form 8-K
Brookline Capital Acquisition : Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination - Form 8-K
Brookline Capital Acquisition : Confirms Receipt of Sponsor Funds to Extend Period of Time to Consummate Business Combination and for Additional Working Capital - Form 8-K
Brookline Capital Acquisition : Quarterly Report (Form 10-Q)
Brookline Capital Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
Brookline Capital Acquisition Corp. announced that it has received $0.167032 million in funding from Brookline Capital Holdings, LLC
Brookline Capital Acquisition : Announces Stockholder Approval of Extension Amendment to Complete its Business Combination with Apexigen, Inc - Form 8-K
Brookline Capital Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2021
Brookline Capital Acquisition Corp. Auditor Raises 'Going Concern' Doubt
Brookline Capital Acquisition : VIAVID communications simplified. Apexigen and Brookline Capital Acquisition Corp. Joint Conference Call - Form 8-K
Brookline Capital Acquisition : Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company - Form 8-K
Blank Check Firm Brookline Capital Acquisition, Apexigen Enter Merger Agreement
Apexigen Inc. entered into a non-binding letter of intent to acquire Brookline Capital Acquisition Corp. from Brookline Capital Holdings, LLC, Periscope Capital Inc, Kepos Capital LP and others for approximately $210 million in a reverse merger transaction.
Brookline Capital Acquisition : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - Form 8-K
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QB4N Aktie
  4. Nachrichten BROE CAPI
  5. Andere Sprachen